Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin and clindamycin periarticular penetration in second-stage hip revision arthroplasty
NL-OMON51548Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2022
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefazolin and clindamycin in periprosthetic joint infection (PJI), sponsored by Radboud University Medical Center. Planned start May 2022; status: not yet recruiting.
02
Drugs
cefazolinclindamycin
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NL-OMON51548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51548.